Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2922MR)

This product GTTS-WQ2922MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2922MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2769MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ1817MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ8042MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ4786MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ9199MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ5465MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ3385MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ8016MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GZ-402668
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW